Case study of a patient who participated in Ixaka’s REX-001 clinical trial

01/12/2020

Ixaka and Minaris Regenerative Medicine Sign Tech Transfer and GMP Manufacturing Agreement for Lead Cell Therapy Candidate REX-001

27/06/2022

REX-001 is an autologous multi-cell therapy (MCT) in development for the treatment of chronic limb-threatening ischemia (CLTI) in patients with…

Ixaka expands IP portfolio to enable use of targeted nanoparticle in vivo gene delivery technology with any cargo in any therapeutic area

21/03/2022

London, UK, 21 March 2022– Ixaka Ltd, an integrated cell and gene therapy company, today announces an expansion of its…

CELTIC-19 granted Advanced Therapy Medicinal Product classification by European Medicines Agency

08/03/2022

CELTIC-19 – Ixaka’s targeted nanoparticle for CD19 haematological malignancies – has been granted Advanced Therapy Medicinal Product (ATMP) classification by…

innovative cell therapies